Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis

European Urology

Volumn 68, Issue 3, 2015, Pages 386-396

  Bosco, Cecilia ^a   Bosnyak, Zsolt ^b   Malmberg, Anders ^b   Adolfsson, Jan ^c   Keating, Nancy L ^d   Van Hemelrijck, Mieke ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Ferring Pharmaceuticals AS   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Cardiovascular disease; Morbidity; Mortality; Prostate cancer

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; GONADORELIN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; FATALITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; MALE; MORTALITY; MYOCARDIAL INFARCTION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RISK FACTOR; STROKE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; ESTROGENS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MYOCARDIAL INFARCTION; ORCHIECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; STROKE;

EID: 84940489417     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.11.039     Document Type: Review

References (60)

1. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol 167 2002 948 951 discussion 952
2. E.D. Crawford Hormonal therapy in prostate cancer: historical approaches Rev Urol 6 Suppl 7 2004 S3 S11
3. M. Bolla, L. Collette, L. Blank, and et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
4. E.M. Horwitz, K. Bae, G.E. Hanks, and et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
5. A. Heidenreich, G. Aus, M. Bolla, and S. Joniau European Association of Urology. EAU guidelines on prostate cancer Eur Urol 53 2008 68 80
6. P.L. Nguyen, Y. Je, F.A.B. Schutz, and et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359 2366
7. A. Nanda, M.-H. Chen, M.H. Braccioforte, B.J. Moran, and A.V. D'Amico Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
8. Ziehr DR, Chen M, Zhang D, et al. Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. In press. http://dx.doi.org/10.1111/bju.12905
9. P.C. Albertsen, L. Klotz, B. Tombal, J. Grady, T.K. Olesen, and J. Nilsson Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist Eur Urol 65 2014 565 573
10. M. Van Hemelrijck, H. Garmo, L. Holmberg, and et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden J Clin Oncol 28 2010 3448 3456
11. M. Van Hemelrijck, J. Adolfsson, H. Garmo, and et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden Lancet Oncol 11 2010 450 458
12. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
13. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
14. L. Azoulay, H. Yin, S. Benayoun, C. Renoux, J.-F. Boivin, and S. Suissa Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer Eur Urol 60 2011 1244 1250
15. C.G. Jespersen, M. Nørgaard, and M. Borre Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study Eur Urol 65 2014 704 709
16. J.C. Hu, S.B. Williams, A.J. O'Malley, M.R. Smith, P.L. Nguyen, and N.L. Keating Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism Eur Urol 61 2012 1119 1128
17. E. Martín-Merino, S. Johansson, T. Morris, and L.A. García Rodríguez Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care Drug Saf 34 2011 1061 1077
18. P.B. Burns, R.J. Rohrich, and K.C. Chung The levels of evidence and their role in evidence-based medicine Plast Reconstr Surg 128 2011 305 310
19. W.K. Kelly, and L.G. Gomella Androgen deprivation therapy and competing risks JAMA 306 2011 2382 2383
20. K. Benson, and A.J. Hartz A comparison of observational studies and randomized, controlled trials N Engl J Med 342 2000 1878 1886
21. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklists. STROBE Statement Web site. http://www.strobe-statement.org/index.php?id=available-checklists.
22. Cardiovascular diseases (CVDs). World Health Organization Web site. http://www.who.int/mediacentre/factsheets/fs317/en/.
23. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, and L. Rushton Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry J Clin Epidemiol 61 2008 991 996
24. R.M. Harbord, R.J. Harris, and J.A.C. Sterne Updated tests for small-study effects in meta-analyses Stata J 9 2009 197 210
25. D.Y. Lin, B.M. Psaty, and R.A. Kronmal Assessing the sensitivity of regression results to unmeasured confounders in observational studies Biometrics 54 1998 948 963
26. P.R. Rosenbaum, and D.B. Rubin Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome J R Stat Soc Ser B 45 1983 212 218
27. T.J. VanderWeele, and O.A. Arah Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders Epidemiology 22 2011 42 52
28. W.B. Kannel, and D.L. McGee Diabetes and cardiovascular risk factors: the Framingham study Circulation 59 1979 8 13
29. Diabetes public health resource. Rate per 100 of civilian, noninstitutionalized population with diagnosed diabetes, by age, United States, 1980-2011. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/diabetes/statistics/prev/national/figbyage.htm.
30. J.S. Tolstrup, U.A. Hvidtfeldt, E.M. Flachs, and et al. Smoking and risk of coronary heart disease in younger, middle-aged, and older adults Am J Public Health 104 2014 96 102
31. Smoking & tobacco use. Adult cigarette smoking in the United States: current estimates. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/tobacco/data-statistics/fact-sheets/adult-data/cig-smoking/index.htm.
32. H.K. Tsai, A.V. D'Amico, N. Sadetsky, M.-H. Chen, and P.R. Carroll Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516 1524
33. M. Braga-Basaria, A.S. Dobs, D.C. Muller, and et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983
34. A.S. Cheung, D. Pattison, I. Bretherton, and et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines Andrology 1 2013 583 589
35. S.-D. Chung, Y.-K. Chen, F.-J. Wu, and H.-C. Lin Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study BJU Int 109 2012 1001 1005
36. A.V. D'Amico, J.W. Denham, J. Crook, and et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
37. J.A. Efstathiou, K. Bae, W.U. Shipley, and et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
38. J.A. Efstathiou, K. Bae, W.U. Shipley, and et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02 Eur Urol 54 2008 816 823
39. B. Ehdaie, C. Atoria, A. Gupta, and A. Feifer Androgen deprivation and thromboembolic events in men with prostate cancer Cancer 118 2012 3397 3406
40. J. Kim, M. Vaid, S. Tyldesley, R. Woods, and T. Pickles Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency Int J Radiat Oncol Biol Phys 80 2011 742 750
41. P.L. Nguyen, M.H. Chen, S.Z. Goldhaber, and et al. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation Cancer 117 2011 406 413
42. P.L. Nguyen, M.-H. Chen, J.A. Beckman, and et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction Int J Radiat Oncol Biol Phys 82 2012 1411 1416
43. S. Punnen, M.R. Cooperberg, N. Sadetsky, and P.R. Carroll Androgen deprivation therapy and cardiovascular risk J Clin Oncol 29 2011 3510 3516
44. M. Roach, K. Bae, J. Speight, and et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
45. D. Robinson, H. Garmo, B. Lindahl, and et al. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden Int J Cancer 130 2012 478 487
46. C.S. Saigal, J.L. Gore, T.L. Krupski, J. Hanley, M. Schonlau, and M.S. Litwin Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500
47. M.R. Smith, L. Klotz, E. van der Meulen, E. Colli, and L.B. Tankó Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix J Urol 186 2011 1835 1842
48. R.D. Tendulkar, G.K. Hunter, C.A. Reddy, and et al. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer Int J Radiat Oncol Biol Phys 87 2013 94 99
49. C. Wilcox, A. Kautto, A. Steigler, and J.W. Denham Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term Oncology 82 2012 56 58
50. N.L. Keating, A. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 104 2012 1518 1523
51. F. Dong, D.C. Skinner, T. John Wu, and J. Ren The heart: A novel gonadotrophin-releasing hormone target J Neuroendocrinol 23 2011 456 463
52. S.S. Kakar, and L. Jennes Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues Cancer Lett 98 1995 57 62
53. J.J. Su, S.K. Park, and T.M. Hsieh The effect of testosterone on cardiovascular disease a critical review of the literature Am J Mens Health 8 2014 470 491
54. F. Dockery, C.J. Bulpitt, S. Agarwal, M. Donaldson, and C. Rajkumar Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia Clin Sci (Lond) 104 2003 195 201
55. C.J. Malkin, P.J. Pugh, R.D. Jones, T.H. Jones, and K.S. Channer Testosterone as a protective factor against atherosclerosis - immunomodulation and influence upon plaque development and stability J Endocrinol 178 2003 373 380
56. H.-F. Chen, E.-B. Jeung, M. Stephenson, and P.C.K. Leung Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor γ-chain messenger ribonucleic acids that are regulated by GnRH in vitro 1 J Clin Endocrinol Metab 84 1999 743 750
57. P. Libby Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis J Lipid Res 50 Suppl 2009 S352 S357
58. G. Grasso The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro Life Sci 62 2014 2005 2014
59. R. Thadhani Formal trials versus observational studies A. Mehta, M. Beck, G. Sunder-Plassmann, Fabry disease: perspective from 5 years of FOS 2006 PharmaGenesis Oxford, UK
60. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64 2013 159 166